Page 12 - நிறுவனம் ஆஃப் ஆர்க்யாநிக் வேதியியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Dracen Announces Clinical Collaboration with Merck Share Article Dracen will develop sirpiglenastat (DRP-104) in combination with KEYTRUDA® in selected patients with Non-Small Cell Lung Cancer NEW YORK (PRWEB) March 08, 2021 Dracen Pharmaceuticals, Inc. (Dracen) announced today that it has entered into a clinical trial and supply agreement with Merck, known as MSD outside the United States and Canada, to evaluate the safety and efficacy of sirpiglenastat (DRP-104), Dracen’s glutamine antagonist, in combination with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 (programmed death receptor-1) therapy, in patients with solid tumors. A Phase 1b trial will enroll locally advanced or metastatic non-small cell lung cancer (NSCLC) patients to establish the safety/tolerability of sirpiglenastat in combination with KEYTRUDA. The trial is expected to begin by first quarter 2022.

New yorkUnited statesSan diegoCzech republicMargaret duganWorld health organizationInstitute of organic chemistryDrug administrationOsage university partnersMerck sharp dohme corpDracen pharmaceuticals incMerck co incExpert committeeDracen pharmaceuticalsChief medical officerFast track